Outlook Therapeutics, Inc.: Form 10-K for the period ended Sep 30, 2023
Filed with the SEC on Dec 22, 2023 and accepted by EDGAR at Dec 22, 2023, 22:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-10-01 to 2023-09-30 | $26.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-10-01 to 2023-09-30 | −$53.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2022-10-01 to 2023-09-30 | $2.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-10-01 to 2023-09-30 | −$59.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-10-01 to 2023-09-30 | −$0.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-10-01 to 2023-09-30 | −$0.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-10-01 to 2023-09-30 | 250,176,633 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-10-01 to 2023-09-30 | −$43.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | $23.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $31.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $32.3m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $46.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $46.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-09-30 | −$14.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-020000. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.